Where to Screen the Next Generation of Cardiovascular-Risk Patients
Lipid testing rates are very low among those under 40 years old. Where do clinicians best target high-risk patients—and how?
Andrew Moran, MD, MPH: The Value of Earlier Lipid Intervention
Adults 40 years and younger generally aren't tested for lipid level risk—a byproduct of national guidance and clinical trial needs.
James Mulshine, MD: Advancements in CT Screening for Lung Cancer
Dr. Mulshine and Dr. Rizzo discuss the diagnostic evolution detailed in several studies in the previous decades, and how CT screening can be used to detect lung cancer early in patients.
Theodore Leng, MD: Characterizing the Definition, Rates of Intermediate Dry AMD
Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.
Robert L. Avery, MD Highlights Results on RGX-314 For the Treatment Of Wet AMD
Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results
Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema
Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.
Deepak Bhatt, MD, MPH: Promising Data From the REVERSE-IT Trial
There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.
Rishi P. SIngh, MD: Advances and Challenges in Neovascular AMD Treatment
Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.
Rishi P. SIngh, MD: Durability of Faricimab in Neovascular AMD Treatment
Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.
Ammara Mushtaq, MD: Understanding C Difficile Infections
There has recently been more community spread of C difficile infections.
Kazuki Yoshida, ScD: Treat-to-Target Proves Safe for Gout Therapy
New ACR findings supporting rheumatology societies' advocacy for more intensive therapy strategies, with proof of safety.
Mena Boules, MD: The Challenge in Finding a Treatment for EoE
There currently is not an approved treatment for EoE by the US Food and Drug Administration.
Marla C. Dubinsky, MD: Finding Biomarkers in IBD
Patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.
Evan S. Dellon, MD: Dupilumab for EoE at ACG 2021
ACG represents the first major in-person conference since the COVID-19 pandemic.
Paul Feuerstadt, MD: The Value of Antimicrobial Stewardship for C Difficile
Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.
Marla C. Dubinsky, MD: Measuring Urgency in Ulcerative Colitis
An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.
Evan S. Dellon, MD: A Daily Diary for Eosinophilic Esophagitis
PROSE allows patients to report their symptoms of dysphagia in real-time.
Ji Seok Park, MD: Collaborating with Other Specialists for IBD Research
Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.
Paul Feuerstadt, MD: RBX2660 and FMT for C Difficile Infections
It can be challenging to find a suitable donor for fecal microbiota transplantation.
Paul Feuerstadt, MD: The Promise of RBX2660 for C Difficile
RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.
Ji Seok Park, MD: The Connection Between Crohn's Disease and Kidney Disease
Patients with Crohn's disease often also suffer from kidney dysfunction.
Marianne M. Glanzman, MD: Helping ADHD Patients Succeed
Dr. Glanzman presented during AAP 2021 about executive function impairments in patients with ADHD.
Marianne M. Glanzman, MD: A Challenging Time for ADHD Patients
Students with ADHD have struggled with virtual schooling during the COVID-19 pandemic.
Sahil Khanna, MBBS: Emerging Therapies for C Difficile
Recent studies have shown the majority of potential FMT donors are ultimately rejected.
Marianne Glanzman, MD: Explaining Executive Function in ADHD
Executive function can include working memory, behavioral inhibition, and cognitive flexibility.
Pursuing Tailored Care for Diabetic Macular Edema
The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.
Factors Influencing Treatment of Diabetic Macular Edema
Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.
Long-Term nAMD Patient Buy-In Is Still Lacking for Anti-VEGF Therapy
Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.
How Virtual Visits, Port Delivery System Therapy Can Benefit Retina Practices
Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.
Assuring Optimal Implant Insertion of Port Delivery Systems for Anti-VEGF
Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.
